This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parnes, H. L. Articles by Ford, L. G. Search for Related Content PubMed PubMed Citation Articles by Parnes, H. L. Articles by Ford, L. G.

Prevention of Hormone-Related Cancers: Prostate Cancer

Howard L. Parnes, Ian M. Thompson, Leslie G. Ford

From the Division of Cancer Prevention, Prostate and Urologic Cancer Research Group, and the Deputy Directors' Office, National Cancer Institute, Bethesda, MD; Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX

Address reprint requests to Leslie G. Ford, MD, National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892; e-mail: lf50z{at}nih.gov.

Androgens are known to play an important role in normal prostate development, benign prostatic hyperplasia, established prostate cancer, and in prostate carcinogenesis. However, despite convincing experimental and clinical evidence, the epidemiologic data correlating sex steroid levels with disease risk is inconsistent. More recent work has focused on studies of polymorphisms in germ-line DNA in an effort to develop polygenic models of prostate cancer susceptibility and prognosis. Such models have the potential to aid in the selection of men for specific chemopreventive interventions and to help determine which men with localized prostate cancer are most likely to benefit from aggressive therapy. In this review, we will provide a brief summary of androgen metabolic pathways followed by an assessment of the epidemiology literature addressing the relationship between androgens and prostate cancer. Finally, we will address the two major questions that have arisen in response to the recently published results from the Prostate Cancer Prevention Trial: Who are the best candidates for finasteride chemoprevention, and what are the clinical implications of the high prevalence of prostate cancer that was detected in men with prostate-specific antigen levels in the so-called "normal" range?

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				S Leskela, E Honrado, C Montero-Conde, I Landa, A Cascon, R Leton, P Talavera, J M Cozar, A Concha, M Robledo, et al. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 645 - 654. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				A. Malik, F. Afaq, S. Sarfaraz, V. M. Adhami, D. N. Syed, and H. Mukhtar Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer PNAS, October 11, 2005; 102(41): 14813 - 14818. [Abstract] [Full Text] [PDF]

				E. S. Ford and S. Liu Invited Commentary: Acne in Adolescence--Protecting the Heart but Damaging the Prostate Later in Life? Am. J. Epidemiol., June 15, 2005; 161(12): 1102 - 1106. [Full Text] [PDF]